Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:08:17.218Z.
Consensus retrieved: 2026-10-06T13:16:07.131Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:08:17.218Z.
Quote observation: 2026-10-06T18:05:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a391670e5a4a022aad0cee8204cefb21b4613c0a4e77d467850b61b24c11a6b7
Forward PE Ratio (N/A) = Dated Quote Price ($31.18) / Consensus Forward EPS ($-3.27)
FORWARD PE RATIO
N/A
Korsana Biosciences, Inc.
Market Cap
$145.97M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $145.97M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $147.81M | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.92M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.02M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $143.75M | 7.16 |
| Nyxoah S.A. (NYXH)vs › | $143.60M | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.14M | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $31.18, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.27 | $-3.27 – $-3.27 | 2 | n/m |
| 2027-12-31 | $-3.58 | $-3.58 – $-3.58 | 2 | n/m |
| 2028-12-31 | $-2.99 | $-3.25 – $-2.74 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
